QNTM

Quantum BioPharma Ltd. (NASDAQ:QNTM) is a Canadian biopharmaceutical company headquartered in Toronto that focuses on developing treatments for challenging neurodegenerative, inflammatory, and metabolic disorders, as well as alcohol misuse disorders. Originally founded as FSD Pharma Inc., the company rebranded to Quantum BioPharma Ltd. in August 2024 to better reflect its strategic focus on biopharmaceutical development. The company operates as a clinical-stage biotech firm with drug candidates in various stages of development, maintaining a dual business model that combines pharmaceutical research with strategic real estate investments.